{"version":"v1","contradiction":{"id":"is-mcas-primary-or-amplification","question":"Is MCAS a primary mast-cell disorder or a downstream amplification of candidate upstream mechanisms?","summary":"Whether mast-cell activation is the disease or a symptom of barrier/sulfide/autonomic candidate upstream mechanisms has direct treatment implications.","positions":[{"id":"mcas-primary","label":"MCAS as primary mast-cell disorder","thesis":"An intrinsic mast-cell hyperactivation tendency is the lesion; mast-cell stabilisation is therefore disease-modifying.","predicts":["Stabiliser monotherapy produces durable remission."],"supportingEvidence":["Familial clustering, KIT mutations in mastocytosis."],"weakeningEvidence":["Most MCAS-pattern patients do not have KIT mutations; partial response to stabiliser monotherapy is common."],"authorPosition":"considered-plausible","evidenceLevel":"emerging"},{"id":"mcas-as-amplification","label":"MCAS as downstream amplification (HCM lens)","thesis":"In the recurrent-SIBO/post-viral population, mast-cell activation is amplification driven by barrier failure, sulfide burden, autonomic dysregulation, or histamine clearance failure.","predicts":["Targeting candidate upstream mechanisms reduces MCAS burden more than stabilisers alone."],"supportingEvidence":["Clinical pattern of MCAS resolution with barrier and bioenergetic restoration."],"weakeningEvidence":["No randomised trial comparing upstream vs. stabiliser-first strategies."],"authorPosition":"preferred","evidenceLevel":"hypothesis"}],"unresolvedQuestions":["Which biomarkers identify the 'amplification' subtype prospectively?"],"arbitratingExperiments":["Stratified intervention trial: stabiliser-first vs. upstream-first in MCAS with overlapping gut features."],"relatedConcepts":["mcas-histamine-patterns"],"relatedArticles":["the-epigenetic-truth-about-why-your-mast-cells-won-t-calm-do"],"relatedClaims":["mast-cell-activation-amplifies-barrier-and-vagal-signaling"],"lastReviewed":"2026-05-11"}}